Close menu




September 23rd, 2020 | 14:13 CEST

Deutsche Bank, Daimler, Triumph Gold: What about these fallen angels?

  • Investments
Photo credits: pixabay.com

When investigative journalists immerse themselves in the world of business, the name of Deutsche Bank is mentioned more and more often. Despite countless legal disputes and fines in recent years, the news flow does not end, the latest accusations being activities that observers call money laundering. The documentation surrounding the business relationship between Donald Trump and Deutsche Bank has cast what was once the world's largest financial institution, in a bad light. Although Trump had owed money to one department of the bank for a long time, another department of the bank lent money to the then dazzling real estate mogul to pay off his debts. Many investors would certainly not have thought that such a transaction, based on the principle of right pocket to left pocket would be possible at all. Deutsche Bank rejected a comment on the above-mentioned incident concerning banking secrecy.

time to read: 2 minutes | Author: Nico Popp
ISIN: DE0005140008 , DE0007100000 , CA8968121043

Table of contents:


    The long case of Deutsche Bank

    However, the recent history of Deutsche Bank is not well received on the stock market. In the last five days alone, the share price has lost more than 9%. On a one-year horizon, the loss is 2%. That does not sound much, but over the last five years the share price has already fallen by almost 70%.

    Apart from legal disputes, low-interest rates are the main burden on the banking business. After the aweful year 2019, the bank wanted to return to profitability for the first time in 2020. But the pandemic is likely to thwart these plans. Given the weak starting position for the banking sector in general and the many construction sites for Deutsche Bank in particular, the share is currently of little interest.

    Lawsuits against Daimler

    Daimler is also regarded as rather uninteresting for investors. The drive revolution in the automotive sector is particularly affecting German premium brands. On a one-year horizon, the share lost about 8%. High costs are still a burden on the group. Nevertheless, after the slump in March, the share price was able to increase significantly and still generate a return of 18.3% on a three-month horizon.

    But dark clouds have recently been gathering over Sindelfingen as well: In connection with the diesel affair, investors have filed a million-euro lawsuit against Daimler and are demanding EUR 250 million in damages. Other lawsuits involve smaller amounts. Although Daimler has a substantial financial cushion, lawsuits always create a bad mood. But investors have every reason to look ahead. The company recently announced the truck division is set to take off, climate-neutrally, thanks to electric and hydrogen.

    Newmont Mining as a shareholder

    The shareholders of Triumph Gold also have a plan in mind. On a one-year horizon, however, the share price is expected to post losses of 34%. The company is searching for gold in the Canadian Yukon region and was able to secure fresh capital in the summer. In the coming months, the flagship project, Freegold Mountain, will be further explored. To date, 39,000 metres have been drilled and approximately two million ounces of gold-equivalent 43-101 mining grade rock have been identified as resources. Thanks to the recent capital injection, the company is now funded through 2021.

    While companies such as Deutsche Bank and Daimler are suffering from the general weakness of their industry in addition to their own misconduct, Triumph Gold sees itself supported by the emerging gold boom. The company is considered a promising gold explorer and already has some prominent shareholders. Amongst others, raw material producer Newmont Mining holds a 12.8% stake in Triumph. Newmont operates in the neighbourhood and could be a potential buyer if the upcoming drill results turn out successfully.

    The Market ignores ambitious plans

    With a market capitalization of around EUR 25 million, a takeover would be easy to achieve, both for Newmont and for many other medium and large gold producers. But this is not yet the case. Triumph initially plans to evaluate existing data to be able to search for new deposits in an even more targeted manner. In the long term, the company is talking about developing a mine itself.

    However, there is still a long way to go until then. So far, the market has hardly priced fantasy into Triumph's share price. Given the upcoming drilling and the positive environment for gold in general, Triumph Gold's share could be more promising than that of the other fallen angels.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read